Spots Global Cancer Trial Database for epithelial ovarian carcinoma
Every month we try and update this database with for epithelial ovarian carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of INCB123667 in Subjects With Advanced Solid Tumors | NCT05238922 | Solid Tumors | INCB0123667 | 18 Years - | Incyte Corporation | |
| A Trial of Weekly Paclitaxel With Oncothermia and Weekly cisPlatin With Oncothermia in Patients With Recurrent or Persistent Ovarian Cancer | NCT02344095 | Epithelial Ovar... Fallopian Tube ... Primary Periton... | weekly paclitax... weekly cisplati... oncothermia | - | Seoul National University Hospital | |
| ICON8: Weekly Chemotherapy in Ovarian Cancer | NCT01654146 | Ovarian Cancer | Carboplatin Carboplatin Paclitaxel Paclitaxel | 18 Years - | Medical Research Council | |
| Intraperitoneal Hyperthermic Chemotherapy in Epithelial Ovarian Carcinoma | NCT00349505 | Epithelial Ovar... Figo Stage IIIC | hyper thermic c... | 18 Years - 65 Years | Gustave Roussy, Cancer Campus, Grand Paris | |
| Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | NCT02611024 | Advanced Solid ... Glioblastoma Soft Tissue Sar... Endometrial Car... Epithelial Ovar... Mesothelioma Gastroenteropan... SCLC Gastric Carcino... Pancreatic Aden... Colorectal Carc... Neuroendocrine ... | Lurbinectedin Irinotecan | 18 Years - | PharmaMar | |
| A Beta-only IL-2 ImmunoTherapY Study | NCT05086692 | Advanced Solid ... Unresectable So... Clear Cell Rena... Triple Negative... Non-Small Cell ... Non-Small Cell ... Colorectal Canc... Gastric Cancer Cervical Cancer Basal Cell Carc... Bladder Cancer Merkel Cell Car... Squamous Cell C... Cutaneous Squam... Pleural Mesothe... Esophageal Canc... Endometrial Car... Solid Tumor Solid Tumor, Ad... MSI-H Solid Mal... Cancer With A H... Epithelial Ovar... Primary Periton... Gastroesophagea... Acral Melanoma Mucosal Melanom... Cutaneous Melan... DMMR Solid Mali... Fallopian Tube ... Ovarian Cancer MSI-H Cancer DMMR Cancer Pancreas Adenoc... Skin Cancer | MDNA11 Pembrolizumab | 18 Years - | Medicenna Therapeutics, Inc. | |
| Study of INCB123667 in Subjects With Advanced Solid Tumors | NCT05238922 | Solid Tumors | INCB0123667 | 18 Years - | Incyte Corporation | |
| Study of INCB123667 in Subjects With Advanced Solid Tumors | NCT05238922 | Solid Tumors | INCB0123667 | 18 Years - | Incyte Corporation | |
| Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy | NCT00377429 | Ovarian Cancer | catumaxomab | 18 Years - | Neovii Biotech | |
| A Trial of Weekly Paclitaxel With Oncothermia and Weekly cisPlatin With Oncothermia in Patients With Recurrent or Persistent Ovarian Cancer | NCT02344095 | Epithelial Ovar... Fallopian Tube ... Primary Periton... | weekly paclitax... weekly cisplati... oncothermia | - | Seoul National University Hospital | |
| Intraperitoneal Hyperthermic Chemotherapy in Epithelial Ovarian Carcinoma | NCT00349505 | Epithelial Ovar... Figo Stage IIIC | hyper thermic c... | 18 Years - 65 Years | Gustave Roussy, Cancer Campus, Grand Paris | |
| N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer | NCT01138137 | Ovarian Carcino... Epithelial Ovar... Primary Periton... | Paclitaxel N-acetylcystein... Cisplatin | 18 Years - 75 Years | OHSU Knight Cancer Institute | |
| ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation | NCT05059444 | Bladder Carcino... Ureter Carcinom... Renal Pelvis Ca... Non-small Cell ... Invasive Breast... Cutaneous Melan... Esophageal Carc... Gastroesophagea... Gastric Adenoca... Pancreatic Aden... Squamous Cell C... Epithelial Ovar... Fallopian Tube ... Endometrial Car... Renal Cell Carc... | Guardant Reveal | 18 Years - | Guardant Health, Inc. | |
| Genetic Testing Decision Aid | NCT05470920 | Epithelial Ovar... Pancreas Adenoc... | Electronic Deci... Pre-Test Geneti... | 18 Years - | Massachusetts General Hospital | |
| Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites | NCT00326885 | Malignant Ascit... | catumaxomab | 18 Years - | Neovii Biotech | |
| Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy | NCT00377429 | Ovarian Cancer | catumaxomab | 18 Years - | Neovii Biotech | |
| ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation | NCT05059444 | Bladder Carcino... Ureter Carcinom... Renal Pelvis Ca... Non-small Cell ... Invasive Breast... Cutaneous Melan... Esophageal Carc... Gastroesophagea... Gastric Adenoca... Pancreatic Aden... Squamous Cell C... Epithelial Ovar... Fallopian Tube ... Endometrial Car... Renal Cell Carc... | Guardant Reveal | 18 Years - | Guardant Health, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
